Linagliptin (10 mg/kg) lowered peak glucose concentration, which occurred at 15 min in all mice, while Ex9 impaired basal glucose and tolerance to an oral glucose load in VilCre control mice but had no effect in Gcg RA VilCre or Gcg RA Null mice (Fig
Roche with its 2024 acquisition of Carmot, and Pfizer, following its 2025 acquisition of Metsera, enter obesity and broaden their presence in cardiovascular/metabolic, while other large pharmaceutical companies prepare to follow later in the decade
Trial Data Phase III trials demonstrated how retatrutide resulted in significant weight loss
Its essential to approach such trends with scepticism and prioritise safety over quick fixes
Marketed as a high-concentration fat dissolve solution containing Riboflavin (vitamin B2) and other undisclosed ingredients, Lemon Bottle claims to accelerate fat cell metabolism and aid in fat decomposition
Different medications have varying levels of efficacy, safety profiles, dosing requirements, potential side effects, and costs
